Investor Presentation

SEB Nordic Healthcare Seminar
January 18, 2022

Donato Spota
CFO

Christian Kjellman
CSO/COO

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

Hansa Biopharma today

Successful track record...
Strong momentum...
Promising future...

A validated technology

VALIDATION ACROSS THREE AREAS

- Approval in kidney transplantations
- Proof of concept in autoimmune diseases
- Partnership to explore gene therapy

Idefirix® is our first approved drug in Europe*

EUROPE KIDNEY TRANSPLANTS

For highly sensitized patients in Europe

Broad pipeline in transplantation and autoimmunity

PROGRAMS IN CLINICAL DEVELOPMENT

US kidney transplants
Anti-GBM
Guillain-Barré syndrome (GBS)
Antibody mediated kidney transplant rejection (AMR)

Established a high-performance organization

NEW COMPETENCIES ADDED

133 employees December 2021 (~3x in 3 years)

Highly qualified team with 20 years on average in life science

Purpose driven culture

With recent capital injection Hansa is financed into 2023

FINANCIALS

SEK 889m in Cash (USD ~98m) December 2021

Created shareholder value and diversified our ownership base

MARKET CAPITALISATION (USD): ~0.4bn

Listed on Nasdaq Stockholm
18,000 shareholders
Foreign ownership make up ~50% through leading international life science specialist funds

*Idefirix approved in EEA under conditional approval for kidney transplantation

**Actual patient has given consent to provide images

Many milestones achieved during the last 18 months



Imlifidase

A novel approach to eliminate pathogenic IgG

Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection



A unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')2 fragment and one homo-dimeric Fc-fragment



Inactivates IgG in 2-6 hours

- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



Potential indication universe



*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients.
**) In the US a new study has commenced targeting a BLA filing by H1 2024

Our Business model

Leveraging our technology platform to develop new therapies targeting rare diseases with unmet medical need across a range of indications



Evolution into a fully integrated biopharmaceutical company

Idefirix® (imlifidase) has received conditional approval in the European Union

Low complexity transplants ⟷ Higher complexity transplants

~70% of patients[1,2]	15-20% of patients[1,2]	10-15% of patients[1,2]
Non or less sensitized (cPRA < 20%)	Moderately sensitized (20% < cPRA < 80%)	Highly sensitized (cPRA > 80%)
		Highly sensitized patients that are likely to be transplanted with a compatible donor
		Highly sensitized patients unlikely to be transplanted under available KAS, including prioritization programs



Actual patient has given consent to provide images

Idefirix® is indicated for

desensitization treatment of highly sensitized adult kidney transplant patients with positive crossmatch against an available deceased donor.

The use of Idefirix® should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritization programs for highly sensitized patients

Potential patients

idefirix® imlifidase

HANSA BIOPHARMA

[1] EDQM. (2020). International figures on donation and Transplantation 2019
[2] SRTR Database and individual assessments of allocation systems

European kidney transplantation landscape

Approximately 28,000 kidney transplants are carried out in Europe annually; ~72% of transplants are from deceased donors[1]



[1] Transplant data from 2019.
*Belgium, Croatia, Cyprus, Greece, Hungary, Iceland, Ireland, Lithuania, Poland, Portugal, Romania, Slovakia, Slovenia
Source: Global Observatory on Donation & Transplantation, 2019

Progress with commercial metrics; Market access procedures are ongoing in thirteen countries

Pricing and Reimbursement processes on track; Completion of HTA filings in EU4+UK expected during Q1 2022

Pricing and Reimbursement

4

✓ Agreements on funding obtained:

- Sweden
- Netherlands
- Finland (on hospital basis)
- Greece (on hospital basis)

✓ Additional milestones

- Preparing for market access in additional international markets beyond Europe and the US (e.g. Israel)
- Pursuing early access opportunities where possible

Market access procedures

13

✓ Market access procedures are ongoing in thirteen countries

- Sweden
- Netherlands
- Finland
- Norway
- Denmark*
- France
- Belgium
- UK
- Germany
- Italy
- Scotland
- Israel
- Greece

✓ Health Technology Assessment (HTA) dossier for Spain is expected to be submitted during Q1 2022 which will complete HTA filings in all the five largest markets in Europe.

** In Denmark, the HTA has been pre-submitted*

Growing number of patient candidates as select priority centers get clinically ready and awareness increased

Clinical readiness

10

✓ Ten priority centers clinical ready to take on patients include among others:

- Akademiska, Uppsala
- Erasmus, Rotterdam
- University Hospital, Helsinki

10

✓ Hansa to continue to work closely with another ten priority centers on clinical readiness

✓ Growing number of highly sensitized patient candidates identified and prioritized for incompatible kidney transplantations in the coming months

Awareness

✓ Over 30 experts are engaged and committed to operationalizing HLA-incompatible kidney transplants for some of their highly sensitized patients.

✓ European Society for Organ Transplantation (ESOT) workstream, formed with leading experts, continued its work on advancing clinical guidelines in the complex field of desensitization; 2nd part of the workstream expected to begin in 2022.

HANSA BIOPHARMA

Broad clinical pipeline in transplantation and auto-immune diseases

[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7)
[2] Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)
[3] Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund
*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients. A post-approval study will commence in parallel with the launch

Completed
Ongoing
Planned
Conditional approval based on Phase 2 data

HANSA BIOPHARMA

Our unique antibody cleaving enzyme technology may have relevance across a range of indications

Targeting rare IgG mediated diseases

Anti-GBM paves the way for development in other autoimmune diseases

- Rapidly progressive glomerulonephritis
- Neurological disorders
- Skin and blood disorders

IgG-cleaving enzymes to enable or even potentiate cancer therapy

- Allogenic stem cell (bone marrow) transplantation (HSCT)
- Enzyme-based antibody Enhancement (EnzE)



Expanding our commercial franchises

- Regulatory approval (conditional)
- Clinical development
- Partnership (preclinical development)
- Preclinical development

Shaping a new standard for desensitization will help enable new indications in transplantations

- Antibody mediated rejection (AMR) in kidney transplantation
- Other transplantation types

Exploring opportunities in gene therapy

- Encouraging preclinical data published in Nature
- Partnership with Sarepta
- Wide indication landscape beyond

HANSA BIOPHARMA

Upcoming milestones

Milestones subject to potential COVID-19 impact




HANSA
BIOPHARMA

Corporate Contacts

Investor Relations and
Corporate Communications

Visit our web site
www.hansabiopharma.com

Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709-298 269

Email: klaus.sindahl@hansabiopharma.com

Katja Margell

Head of Corporate Communications

Mobile: +46 (0) 768-198 326

Email: katja.margell@hansabiopharma.com

Calendar and events

Feb 3, 2022	Year-End report for Jan - Dec 2021
Mar 10, 2022	Erik Penser Bolagsdag, Stockholm
Mar 10, 2022	Redeye Investor Forum, Gothenburg
Mar 15, 2022	Carnegie Healthcare Seminar 2022, Stockholm
Mar 31, 2022	Redeye Investor Forum, Malmö
April 7, 2022	Annual Report 2021
April 21, 2022	Interim Report for January-March 2022
April 21, 2022	Kempen Life Sciences Conference 2022, Amsterdam
April 27, 2022	Redeye Orphan Drugs 2022, Stockholm
May, 2022	RBC Global Healthcare Conference 2022, New York City
June 16, 2022	Annual General Meeting 2022
July 21, 2022	Half year 2022 report
Oct 20, 2022	Interim Report for January-September 2022

HANSA BIOPHARMA